MOUD Buprenorphine Sublocade denied due to quantity / dose limits by Express Scripts?

Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.

Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.

## Why Express Scripts Limits Quantity for Sublocade — and How to Appeal

Express Scripts (ESI) applies quantity limits to Sublocade (buprenorphine extended-release subcutaneous injection) as part of its utilization management framework. Because Sublocade is dosed on a monthly administration schedule, quantity limits typically govern the number of injections per rolling period. Denials arise when a claim exceeds the approved quantity — for example, if a patient's treatment schedule or a pharmacy fill pattern places two claims within a period the plan treats as a single cycle.

These denials are often resolvable with clarifying documentation. They can also reflect an underlying formulary or PA issue that needs to be addressed at the same time.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the denial. ESI-administered plans must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited review: If the quantity limit is preventing timely dosing for a patient in active MOUD treatment, request expedited internal review — plans must respond within 72 hours.
• External independent review (ACA §2719): If internal appeal is denied, you have approximately four months from the original denial to initiate external review by an independent organization. Quantity-limit denials are reviewable on both procedural and clinical grounds.
• MHPAEA parity: If quantity limits on MOUD medications are more restrictive than comparable limits on treatments for analogous medical conditions, raise a parity argument explicitly in the appeal.

## The Appeal Process

1. Confirm the exact quantity limit the plan is applying and whether it is a per-fill, per-month, or per-rolling-period restriction. 2. Determine whether the excess quantity reflects a scheduling issue (timing of injections) or a genuine clinical need for a modified schedule. 3. Gather documentation addressing the clinical rationale for the quantity or schedule requested. 4. File a written internal appeal with a prescriber letter and supporting chart documentation. 5. Request external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis and treatment plan: DSM-5 opioid use disorder diagnosis, current treatment plan including intended dosing schedule, and prescribing clinician credentials.
• Administration schedule rationale: If the fill pattern that triggered the limit reflects a clinically appropriate schedule (e.g., an induction injection followed by a maintenance injection within the same calendar period), the prescriber should document this explicitly, referencing the FDA-approved dosing framework without stating specific intervals.
• Treatment continuity documentation: Chart notes demonstrating the patient is engaged in and responding to treatment, supporting the medical necessity of uninterrupted dosing.
• Prescriber medical-necessity letter: A letter explaining why the quantity requested is consistent with the FDA-approved prescribing information for Sublocade and with applicable ASAM/SAMHSA treatment guidelines, individualized to this patient's clinical circumstances.
• Impact of denial: Documentation of the clinical risk if the injection is delayed — treatment continuity is central to MOUD effectiveness.

## Criteria-Mapping Structure

| Plan Quantity-Limit Criterion | Supporting Documentation | |---|---| | Approved quantity per period | [Prescription and administration records showing dates and quantities] | | Clinical rationale for requested quantity | [Prescriber letter with schedule justification] | | Consistent with FDA-approved dosing | [Prescriber attestation citing label] | | Medical necessity for uninterrupted treatment | [Chart notes; clinical risk of delay documented] |